SynthesisTranslational psychiatry2021
Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients.
Synthesis in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Pharmacogenomic scores in psychiatry: systematic review of current evidence.Translational psychiatry · 2024Pooled it
- Using multi-trait polygenic scores to predict lithium responsiveness in patients with bipolar disorder.medRxiv : the preprint server for health sciences · 2026Article
- The impact of collider bias on genetic prediction in psychotic disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Leveraging genomic and transcriptomic data of diverse ancestry to uncover mechanisms of psychiatric risk in the adult and developing brain.Nature communications · 2025Article
- Genomics of schizophrenia, bipolar disorder and major depressive disorder.Nature reviews. Genetics · 2025Review
- Polygenic Contributions to Lithium Augmentation Outcomes in Unipolar Depression.JAMA psychiatry · 2025Article
- Pathway-Specific Polygenic Scores for Predicting Clinical Lithium Treatment Response in Patients With Bipolar Disorder.Biological psychiatry global open science · 2025Article
- Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025Review
- Translating Molecular Psychiatry: From Biomarkers to Personalized Therapies-A Narrative Review.International journal of molecular sciences · 2025Review
- Multi-omics approaches for understanding gene-environment interactions in noncommunicable diseases: techniques, translation, and equity issues.Human genomics · 2025Review
- Transdiagnostic Effects of Schizophrenia Polygenic Scores on Treatment Outcomes in Major Psychiatric Disorders.Neuropsychiatric disease and treatment · 2025Review
- How Real-World Data Can Facilitate the Development of Precision Medicine Treatment in Psychiatry.Biological psychiatry · 2024Review
- Clinical and genetic contributions to medical comorbidity in bipolar disorder: a study using electronic health records-linked biobank data.Molecular psychiatry · 2024Article
- Exploring the genetics of lithium response in bipolar disorders.International journal of bipolar disorders · 2024Article
- New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacological reviews · 2024Review
- Immunogenetics of lithium response and psychiatric phenotypes in patients with bipolar disorder.Translational psychiatry · 2024Article
- Effectiveness of ultra-long-term lithium treatment: relevant factors and case series.International journal of bipolar disorders · 2024Review
- Identification of gene networks jointly associated with depressive symptoms and cardiovascular health metrics using whole blood transcriptome in the Young Finns Study.Frontiers in psychiatry · 2024Article
- Pharmacogenomics and response to lithium in bipolar disorder.Pharmacogenomics · 2024Review
- Exploring the genetics of lithium response in bipolar disorders.Research square · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
117 authors at 20 institutions in 15 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs widely between individuals. The molecular mechanisms underlying treatment response heterogeneity are not well understood, and personalized treatment in BD remains elusive. Genetic analyses of the lithium treatment response phenotype may generate novel molecular insights into lithium's therapeutic mechanisms and lead to testable hypotheses to improve BD management and outcomes. We used fixed effect meta-analysis techniques to develop meta-analytic polygenic risk scores (MET-PRS) from combinations of highly correlated psychiatric traits, namely schizophrenia (SCZ), major depression (MD) and bipolar disorder (BD). We compared the effects of cross-disorder MET-PRS and single genetic trait PRS on lithium response. For the PRS analyses, we included clinical data on lithium treatment response and genetic information for n = 2283 BD cases from the International Consortium on Lithium Genetics (ConLi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.